Search details
1.
Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.
J Neurooncol
; 166(2): 351-357, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38244173
2.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(5): 503-513, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37156478
3.
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Eur J Haematol
; 111(6): 863-871, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37670560
4.
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Cancer
; 128(7): 1411-1417, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-34931301
5.
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility.
Haematologica
; 106(8): 2114-2120, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-32646891
6.
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.
Hematol Oncol
; 39(5): 697-706, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34499366
7.
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis.
J Natl Compr Canc Netw
; : 1-10, 2021 Jun 22.
Article
in English
| MEDLINE | ID: mdl-34161925
8.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
J Natl Compr Canc Netw
; 19(1): 16-27, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33406488
9.
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Cancer
; 125(18): 3121-3130, 2019 Sep 15.
Article
in English
| MEDLINE | ID: mdl-31291012
10.
Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.
Haematologica
; 107(7): 1709-1713, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-35236053
11.
Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Clin Adv Hematol Oncol
; 15(8): 632-642, 2017 Aug.
Article
in English
| MEDLINE | ID: mdl-28949951
12.
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis.
Cancer
; 121(12): 2004-12, 2015 Jun 15.
Article
in English
| MEDLINE | ID: mdl-25739348
13.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Haematologica
; 104(4): e143-e146, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30409798
14.
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
Res Sq
; 2024 Mar 11.
Article
in English
| MEDLINE | ID: mdl-38559108
15.
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
JAMA Oncol
; 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38722664
16.
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Transplant Cell Ther
; 2024 May 05.
Article
in English
| MEDLINE | ID: mdl-38710302
17.
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
J Hum Genet
; 58(6): 353-61, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23677058
18.
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.
Haematologica
; 103(3): e106-e109, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29242304
19.
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
Leuk Lymphoma
; 64(5): 990-996, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36891630
20.
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Leukemia
; 37(9): 1915-1918, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37524919